Biofarm doubles profits in H1

Pharmaceuticals company Biofarm Bucharest has concluded the first six months of the year with 7.6 million RON (2.15 million euros) in net profits, its preliminary results reveal – an increase of over 100% in RON on the same time last year. “These are preliminary data and will be certified as soon as the audit for this period is over,” said Dan Vasile, Biofarm”s general manager. The company”s net profits for the first three months of the year reached 1.3 million euros, representing around 40% of Biofarm”s sales. The net margin in excess of 30% in the company”s business was retained six months into the year. “The growth in profitability is a direct consequence of the GMP (Good Manufacturing Practice) investments in upgrades and compliance with international standards for all our production lines (pharmaceuticals, tablets, pills, capsules and jellies) and the implementation of efficiency and cost cutting systems,” added Vasile. ZF